Skip To Content
December 17, 2019

Rep. Trone Secures $41.7 Billion for NIH and Alzheimer’s Research

FOR IMMEDIATE RELEASE

Contact: Hannah Muldavin, Hannah.Muldavin@mail.house.gov 

Rep. Trone Secures $41.7 Billion for NIH and Alzheimer’s Research

WASHINGTON, DC – Today, Rep. David Trone (MD-06) hailed a record-high $41.7 billion for the National Institutes of Health (NIH) to conduct life-saving medical research in this year’s Labor, Health and Human Services, and Education Appropriations bill. Trone worked closely with Chairman Roy Blunt (R-MO) and Chairwoman Rosa DeLauro (D-CT) to secure this $2.6 billion increase in funding over last year’s funding level. The NIH funding includes $2.8 billion for Alzheimer’s disease research. 

Last week, Trone called for increased funding levels for both NIH and Alzheimer’s research and spoke to dozens of Members of Congress and Senators to make the case for this increase. The funding is included in one of two government funding bills the House of Representatives passed today.

“If we don’t act now to find a cure, Alzheimer’s will continue to devastate millions of Americans and the disease will bankrupt our country,” said Congressman David Trone. “This record funding for NIH will help us build a better future for our children, find a cure for diseases like Alzheimer’s and cancer, and invest in the health of all Americans. I couldn’t be more thrilled that on a bipartisan basis, our country made a smart investment in research for our children and for our future.”

Congressman David Trone was elected to the House of Representatives in November 2018 to serve the 6th District of Maryland, which includes all or part of Montgomery, Frederick, Washington, Allegany, and Garrett Counties. Since coming to Congress, securing funding for medical research has been one of his top priorities. In June, he led a bipartisan group of freshmen representatives to visit the NIH and meet with Director Francis Collins on their efforts to find cures for some of the world’s most devastating diseases.

###